The Sahajanand Medical Technologies IPO is scheduled to hit the primary market on 15 Oct 2026, with bidding closing on 19 Oct 2026. Key details on record: a ₹475 Cr book-built issue, price band of ₹327–₹344 per share, grey market premium of +₹42 (+12.2%). Shares are expected to list on 23 Oct 2026.
Last updated: 14 Oct 2026, 00:19 IST · auto-refreshed from live GMP, subscription feeds and the company's RHP
| Date | GMP | Est. Gain |
|---|---|---|
| 13 Oct | +₹42 | +12.2% |
| 12 Oct | +₹35 | +10.2% |
Est. gain = GMP as % of the upper band price (indicative listing premium).
Unlisted shares of Sahajanand Medical Technologies are changing hands at a premium of +₹42 over the issue price, with the premium climbing through the day. That implies an indicative listing near ₹386, roughly +12.2% above the upper band. For one retail lot of 43 shares, that translates to an estimated paper profit of about ₹1,806.
GMP is an unofficial, unregulated market signal. It moves daily and does not guarantee the actual listing price. The grey market premium is an unofficial, off-exchange quote where shares change hands before listing. A rising GMP usually means the market expects a strong debut; a fading one suggests cooling enthusiasm. SEBI does not recognise grey-market trades, there is no settlement guarantee, and the actual listing price is decided by normal order-book demand on debut day.
Plan your bid with our unique tools — all calculations run in your browser:
One market lot comprises 43 shares. Applications above ₹2 lakh fall under the non-institutional (HNI) category.
Mark these dates, the full subscription-to-listing cycle typically wraps up in under two weeks. India now runs on a T+3 settlement cycle, meaning bidding closes, allotment is finalised and shares hit Demat accounts within roughly three working days of the close, with listing following the very next trading day. Refunds for unsuccessful applicants happen automatically, ASBA/UPI blocks are released without any forms or follow-ups:
Subscription figures will appear here once bidding opens and the registrar/exchange begins publishing demand data.
QIB demand reflects what mutual funds, insurers and alternative funds think of the valuation; NII (HNI) bookings often track expected listing pops; retail demand shows crowd sentiment. A book that is strong across all three categories is far more reassuring than one carried by a single segment. Remember: heavier oversubscription also means a lottery-style retail allotment, so apply only what you can comfortably bid for.
On a restated consolidated basis, the company revenue increased by 18% and profit after tax (PAT) rose by 175% between the financial year ending with March 31, 2026, a useful one-line read on operating momentum heading into the listing.
Here is how the books have moved over the last three financial years:
| Particulars | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 |
|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 |
| Profit After Tax | 15.09 | 69.08 | 25.15 |
| EBITDA | 48.58 | 170.66 | 128.02 |
| Net Worth | 631.72 | 616.05 | 545.23 |
| Reserves | 706.86 | 692.48 | 580.71 |
| Total Borrowings | 320.63 | 269.53 | 224.96 |
All figures in ₹ Crore unless stated otherwise. Source: restated financials disclosed in the offer documents.
Total change is the full swing from the oldest to the newest restated year and is what the Financial Growth score uses. CAGR is the same journey expressed per year, which stops a small base year from making a large-looking jump. Margin is profit after tax as a share of total income.
Profits have scaled from ₹25.15 Cr to ₹15.09 Cr over two years; the borrowings-to-net-worth ratio has climbed to about 0.51. For investors, the trend matters more than any single year, steady compounding with contained leverage is what institutional bidders typically reward, while a late spike in borrowings deserves scrutiny against the stated objects of the issue.
Reading these numbers. RoE and RoCE measure how efficiently the business turns shareholder capital into profit; anything in double digits is respectable, mid-twenties plus is strong. A debt-to-equity ratio well below 1 signals a balance sheet that does not depend on lenders. NAV per share anchors the book value of your bid, while price-to-book tells you how many rupees the issue is charging for each rupee of that book, compare it with listed peers in the same sector before deciding whether the premium is justified.
The issue price converts into a different earnings multiple once the fresh shares hit the books. Here is the dilution-adjusted picture:
Pre-IPO figures are computed on the pre-issue share count; post-IPO figures assume full subscription at the upper band.
As disclosed under "Competitive Strengths" in the company's offer document.
Promoter holding comes down after the issue. Some dilution is inherent to every IPO, the question is whether the fresh-money component is funding growth (capacity, debt reduction) or simply an exit for early shareholders. Weigh the split between the fresh issue and the offer-for-sale alongside this number before forming a view.
visit MUFG Intime India Pvt.Ltd., open the IPO status page, select "Sahajanand Medical Technologies IPO", enter PAN or application number and view your status.
Enter your application number and PAN on the exchange allotment page to see the shares allotted.
The mandate shows "blocked" until allotment, then the amount is either debited for allotted shares or released automatically.
Shares are scheduled to list on 23 Oct 2026.
Grey-market math points to an indicative listing near ₹386 (+12.2%); with an AI-predicted listing move of 7.6%.
New listings open with a special pre-open call auction: the exchange matches buy and sell orders to discover an opening price, after which normal trading begins. Newly listed counters trade in price bands (circuit limits) on day one, which caps how far the stock can swing from its base price. If you applied and were allotted, shares are already in your Demat before the bell, you can sell at open or hold; if you missed the allotment, you can still buy on debut, but chasing a euphoric opening is a well-known way to overpay.
A detailed business-model breakdown is added by the research desk once the official prospectus (DRHP/RHP) disclosures are fully parsed.
Peer group as disclosed under "Basis for Issue Price" in the RHP
Values as printed in the RHP; compare against the issue's own post-IPO P/E before judging valuation.
Peer comparison data is not available in the RHP for this issue. Some SME IPOs do not include a peer group section in the offer document.
The stated objects, typically a mix of debt repayment, working-capital funding, capacity expansion and general corporate purposes, are set out in the Red Herring Prospectus. The DostIpo desk summarises the object-by-object break-up here once the RHP is parsed in full; until then, treat the prospectus as the authoritative source.
Verify every claim against the primary source. These are statutory public disclosures filed with SEBI / the Registrar of Companies, free to read, no registration needed:
Official SEBI filing with the complete and authoritative picture.
Open RHP →Quick PDF summary of the issue for fast reading.
Open PDF →Links point to SEBI's official filings repository. The RHP contains the authoritative financials, risk factors, promoter details and objects of the issue.
Applying takes under five minutes if your Demat account and UPI ID are ready. There are two standard routes:
Open Zerodha Console, Groww, Upstox, Angel One or any UPI-enabled broker, go to the Invest/Orders IPO section, select Sahajanand Medical Technologies, enter your lot quantity and bid price (or choose cut-off), add your UPI ID and approve the mandate in your UPI app. Funds stay blocked in your own account until allotment, nothing leaves upfront.
Log in to your bank’s net-banking, find the IPO/ASBA section, pick the issue, enter your Demat DP ID and bid details, then submit. The exact amount is blocked and released automatically if no shares are allotted.
Track Sahajanand Medical Technologies IPO GMP day-by-day on the dedicated GMP page →
The sections below are generated automatically by the DostIpo intelligence engine from timestamped snapshots: RHP disclosures, live subscription captures and grey-market tracking. Every claim traces back to a stored data point; where inputs are still missing, the engine says so instead of filling gaps.
Composite of seven weighted categories, category-by-category evidence below.
How complete and internally consistent the inputs behind the 16/100 X-Ray score are — this is not a prediction accuracy claim.
Checks: Price band is present and matches across prospectus and exchange filings. Status: Verified by the consistency engine — no conflict across sources.
Checks: Open, close, allotment and listing dates are present and chronological. Status: Verified by the consistency engine — no conflict across sources.
Checks: Issue size agrees with the objects-of-the-issue maths. Status: Verified by the consistency engine — no conflict across sources.
Checks: Subscription figures are captured and pass sanity bounds. Status: Not available yet — shown as missing, never scored as if present.
Checks: Lot size is present and consistent with price-band maths. Status: Verified by the consistency engine — no conflict across sources.
Checks: A grey-market quote exists with enough history to read a trend. Status: Verified by the consistency engine — no conflict across sources.
Checks: RHP sections extracted: business, risks, peers, industry, objects. Status: Present with a soft inconsistency — usable, but flagged.
Checks: Listed-peer table extracted from the RHP for valuation context. Status: Verified by the consistency engine — no conflict across sources.
Checks: Share of the seven X-Ray pillars actually scored versus left pending. Status: Present with a soft inconsistency — usable, but flagged.
GMP implies 12% listing premium on the upper band (capped at 10% of the score — unofficial signal)
Formula: score = min(|GMP| / upper_band x 100 / 60, 1) x 10 (full 10 at >=60% implied premium; no quote -> skipped, never 0; GMP is only 10% of Fundamental X-Ray by design)
This IPO: min(12.2/60, 1) x 10 = 2.0 -> 2/10
Full rulebook: Data Methodology → X-Ray formula
Bidding has not opened or live figures unavailable — category skipped, not scored 0
Formula: base = min(total_x / 10, 1) x 15; with QIB: score = base x 0.7 + min(qib_x / 5, 1) x 15 x 0.3
Full rulebook: Data Methodology → X-Ray formula
PAT moved from Rs25.15 Cr to Rs15.09 Cr (-40% total across restated years); PAT CAGR -23%/yr over 2 yr, Revenue CAGR -42%/yr, PAT margin +1.9pp
Formula: score = min(pat_growth_pct / 80, 1) x 20, pat_growth_pct = (newest - oldest) / |oldest| x 100 across restated years (simple change, NOT CAGR). The score uses total change; PAT CAGR, Revenue CAGR and PAT-margin trend are displayed alongside as evidence but are NOT scored
This IPO: (15.09-25.15)/|25.15|x100 = -40.0%; min(-40.0/80, 1) x 20 = 0.0 -> 0/20 | CAGR (shown, not scored) = (15.09/25.15)^(1/2)-1 = -22.5%/yr
Full rulebook: Data Methodology → X-Ray formula
Post-IPO P/E of 57.91x looks expensive; leaves little room for disappointment
Formula: post-issue P/E <= 25 -> 18; <= 40 -> 12; else 5 (max achievable is 18/20 by design — perfection is not claimable pre-listing)
This IPO: P/E 57.91x falls in bucket 'expensive' -> 5/20
Full rulebook: Data Methodology → X-Ray formula
promoters retain 36.20% post-issue
Formula: base = 8 if pre-holding >= 65% else 5 if >= 45% else 3; +2 if fresh_share >= 50% (cap 10)
This IPO: pre-holding 40.82% -> base 3 -> 3/10
Full rulebook: Data Methodology → X-Ray formula
low debt/equity at 0.33; EBITDA margin stable/up at 14%; 3 material litigation item(s) per RHP (-6); 3 related-party transaction(s) per RHP (-3)
Formula: start 0; D/E<=0.5 +5, <=1.0 +3; margin stable/up +4; fresh>OFS +2; clean RHP read +4; -2 per litigation item (max -6); -1 per related-party item (max -3); regulatory flag -3; clamp 0..15
This IPO: start 0; D/E 0.33<=0.5 -> +5; margin 12%->14% stable/up -> +4; 3 litigation -> -6; 3 related-party -> -3 = 0 -> clamp 0..15 -> 0/15
Full rulebook: Data Methodology → X-Ray formula
Post-issue P/E 57.91x vs RHP peer median 51.4x (Medical Devices & MedTech): slight premium to peer median (1.13x)
Formula: ratio = post_PE / peer_median_PE: <=0.80 -> 10; <=1.00 -> 8; <=1.25 -> 6; <=1.60 -> 4; else 2 (fallbacks: industry bullets -> 7, sector only -> 6)
This IPO: ratio 57.91/51.4 = 1.13 -> bucket -> 6/10
Full rulebook: Data Methodology → X-Ray formula
| Strongest Pillar | Industry (6/10) |
|---|---|
| Weakest Pillar | Financial Growth (0/20) |
This is an automated reading of the evidence above, not investment advice.
1/3 signals signals contributed.
gmp velocity 83/100
Market sentiment is significantly stronger than fundamental strength; the grey market is pricing in more optimism than the balance sheet alone supports.
Litigation involving our Group Companies which may have a ma; Companies which may have a material impact on our Company. (Source: AI-read of full RHP)
For details of the related party transactions, as per the re; ‘Related Party Disclosures’ for the three months period ende (Source: AI-read of full RHP)
Post-IPO P/E of 57.91x leaves little room for disappointment. (RHP valuation table)
PAT grew just -40% across restated years (Rs25.15 Cr to Rs15.09 Cr). (Restated financials)
Borrowings climbed from Rs224.96 Cr to Rs320.63 Cr over the restated years. (Restated financials)
All intelligence outputs are data-based observations for education, not recommendations. Methodology: see the Data Methodology page.
| Strongest Pillar | Industry (6/10) |
|---|---|
| Weakest Pillar | Financial Growth (0/20) |
DostIpo is not SEBI-registered. This is an automated, data-based signal for education only. Read the RHP risk factors and consult a SEBI-registered adviser; whether to invest is entirely your decision.
The price band is ₹327–₹344 per share.
Lot size is 43 shares; minimum estimated investment ~₹14,061 (lower band).
The IPO opens on 15 Oct 2026 and closes on 19 Oct 2026.
The allotment date is 21 Oct 2026 (official registrar/exchange date; minor delays are possible).
Estimated grey market premium is +₹42. GMP is unofficial and not a listing-price guarantee.
DostIpo's model gives an indicative 7.6% listing-range estimate (data signal, not guaranteed). Any application decision should follow your own research and risk assessment.
Listing is scheduled for 23 Oct 2026 on BSE, NSE. The listing price is set by market demand on debut day, GMP is only an unofficial hint.
MUFG Intime India Pvt.Ltd. is managing the issue. Allotment status can be checked on its official portal using PAN, application number or DP/client ID once the basis of allotment is finalised.
You can apply through any UPI-enabled broking app (Zerodha, Groww, Upstox, Angel One etc.) or via ASBA through your bank's net-banking. One lot is the minimum application; retail applications are capped at ₹2 lakh.
Subscription shows how many times the shares on offer were bid for. A figure above 1x means the category is oversubscribed. Higher retail and QIB demand generally signals stronger conviction, though it also means lottery-based allotment.
Last updated: 14 Oct 2026, 00:19 IST